Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

NACompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

June 2, 2022

Study Completion Date

June 2, 2022

Conditions
Parkinson Disease
Interventions
DRUG

Apomorphine

Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient

DRUG

Dopaminergic Agonist + Apomorphine

Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists

Trial Locations (6)

30029

CH Caremeau, Nîmes

34295

Hôpital Gui de Chauliac, Montpellier

35033

CHU de Rennes, Rennes

51100

CHU de Reims- hôpital Maison Blanche, Reims

75013

CHU La Pitié Salpêtrière, Paris

76000

CHU Charles Nicolle, Rouen

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT03693872 - Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals | Biotech Hunter | Biotech Hunter